Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prospective Liver Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hyun Kevin Kim, Emory University
ClinicalTrials.gov Identifier:
NCT01539993
First received: February 15, 2012
Last updated: May 23, 2014
Last verified: May 2014
  Purpose

This study is designed for patients diagnosed with Liver cancer to collect information about the relationship between types of liver cancer, methods of treatment and outcomes over time.


Condition
Liver Cancer

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prospective Analysis of Liver Cancer Treatment and Interventions

Resource links provided by NLM:


Further study details as provided by Emory University:

Primary Outcome Measures:
  • Assess efficacy of percutaneous and transarterial treatments for liver cancer. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    QOL questionnaire will be collected during follow up visit.


Secondary Outcome Measures:
  • long term follow up [ Time Frame: 3 months, 6 months 1year ] [ Designated as safety issue: No ]
    Patients will be administered QOL during 3 months, 6 months and 1 year follow up.


Enrollment: 400
Study Start Date: November 2008
Study Completion Date: January 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients 18 yrs and older with a diagnosis of Hepatocellular carcinoma and elegible for percutaneous liver treatments

Criteria

Inclusion Criteria:

  • Patients diagnosed with Hepatocellular carcinoma and referred for percutaneous liver treatment.

Exclusion Criteria:

  • Severe liver disfunction
  • Active uncontrolled infection
  • Significant underlying medical of physical illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01539993

Locations
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Kevin S Kim, MD Emory University
  More Information

No publications provided

Responsible Party: Hyun Kevin Kim, MD FSIR, Director of Interventional Radiology and Image-Guided Medicine., Emory University
ClinicalTrials.gov Identifier: NCT01539993     History of Changes
Other Study ID Numbers: IRB00014768
Study First Received: February 15, 2012
Last Updated: May 23, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
Hepatocellular carcinoma
Liver metastases
Cholangiocarcinoma
Percutaneous treatments
RFA
TACE
DEB

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Liver Diseases
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on November 25, 2014